Several companies announced major developments on July 16, including licensing deals for Merck and LaNova, a collaboration for BNT327, and the impact of Medicare Part D on Eliquis sales.
2 reports, 1 independent
Updated Jul 16
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Several companies announced major developments on July 16, including licensing deals for Merck and LaNova, a collaboration for BNT327, and the impact of Medicare Part D on Eliquis sales.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Pfizer inked a licensing deal with 3SBio, while Merck licensed LaNova's LM-299.1 source
- Pfizer and BMY co-develop Eliquis; FDA approves Opdivo and xanomeline.
Keep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Merck
public company in Indonesia
-
BioNTech
Biotechnology company from Germany
Nothing else this week.
-
Bristol-Myers Squibb
American pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- ZacksWill Increased Expenses Affect Bristol Myers' Performance? Last month, Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-c
- Unknown outlet